Toyota|$17.89 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.03 (¥3,957)-2.78%▼ (in JPY terms)
SoftBank|$29.62 (¥4,682)+4.65%▲ (in JPY terms)
MUFG|$21.36 (¥3,377)+0.21%▲ (in JPY terms)
Keyence|$500.94 (¥79,190)+0.14%▲ (in JPY terms)
Nintendo|$52.57 (¥8,311)-1.68%▼ (in JPY terms)
NTT|$1.09 (¥172)-1.21%▼ (in JPY terms)
Takeda|$39.90 (¥6,307)-1.56%▼ (in JPY terms)
Tokyo Electron|$62.02 (¥9,805)+4.42%▲ (in JPY terms)
Recruit|$118.92 (¥18,800)+0.40%▲ (in JPY terms)
ITOCHU|$14.62 (¥2,311)-2.32%▼ (in JPY terms)
Honda|$11.15 (¥1,763)-1.45%▼ (in JPY terms)
Shin-Etsu|$37.98 (¥6,004)+2.63%▲ (in JPY terms)
Tokio Marine|$3.51 (¥555)-4.08%▼ (in JPY terms)
Fast Retailing|$465.07 (¥73,520)-0.33%▼ (in JPY terms)
Toyota|$17.89 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.03 (¥3,957)-2.78%▼ (in JPY terms)
SoftBank|$29.62 (¥4,682)+4.65%▲ (in JPY terms)
MUFG|$21.36 (¥3,377)+0.21%▲ (in JPY terms)
Keyence|$500.94 (¥79,190)+0.14%▲ (in JPY terms)
Nintendo|$52.57 (¥8,311)-1.68%▼ (in JPY terms)
NTT|$1.09 (¥172)-1.21%▼ (in JPY terms)
Takeda|$39.90 (¥6,307)-1.56%▼ (in JPY terms)
Tokyo Electron|$62.02 (¥9,805)+4.42%▲ (in JPY terms)
Recruit|$118.92 (¥18,800)+0.40%▲ (in JPY terms)
ITOCHU|$14.62 (¥2,311)-2.32%▼ (in JPY terms)
Honda|$11.15 (¥1,763)-1.45%▼ (in JPY terms)
Shin-Etsu|$37.98 (¥6,004)+2.63%▲ (in JPY terms)
Tokio Marine|$3.51 (¥555)-4.08%▼ (in JPY terms)
Fast Retailing|$465.07 (¥73,520)-0.33%▼ (in JPY terms)

admin

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be installed in Iwata City, Shizuoka Prefecture, and a demonstration experiment will begin in April. Collaboration with the city will be carried out to verify its use in the event of a disaster.”

by

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be in … 続きを読む

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in cisplatin-eligible muscle-invasive bladder cancer were presented at the 2026 American Society of Clinical Oncology (ASCO GU) Annual Meeting.”

by

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate … 続きを読む

Contact